Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1222 Demonbreun Street, Suite 2000 NASHVILLE TN 37203 |
Tel: | 1-510-2796886 |
Website: | https://www.revance.com |
IR: | See website |
Key People | ||
Mark J. Foley Chief Executive Officer, Director | Tobin C. Schilke Chief Financial Officer | David A. Hollander Chief Medical Officer, Global Therapeutics Franchise Lead |
Erica Jordan Chief Commercial Officer | Dwight Moxie Chief Legal Officer |
Business Overview |
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers. |
Financial Overview |
For the three months ended 31 March 2024, Revance Therapeutics Inc revenues increased 13% to $51.9M. Net loss before extraordinary items increased 2% to $49.5M. Revenues reflect Collaboration revenue increase of 87% to $217K. Higher net loss reflects Selling and Adminstative balance increase of 22% to $60.2M (expense), Interest expense - Balancing value increase of 33% to $5.2M (expense). |
Employees: | 534 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $468.20M as of Mar 31, 2024 |
Annual revenue (TTM): | $236.65M as of Mar 31, 2024 |
EBITDA (TTM): | -$201.00M as of Mar 31, 2024 |
Net annual income (TTM): | -$313.72M as of Mar 31, 2024 |
Free cash flow (TTM): | -$220.74M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | $152.77M as of Mar 31, 2024 |
Shares outstanding: | 104,448,502 as of Apr 30, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |